Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Cholesterol Drug Filing Set Back Due To Liver Enzyme Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Takeda had planned to file TAK-475 in the first quarter of 2008 but is now awaiting additional study data.

You may also be interested in...



Takeda Discontinues Development Of Cholesterol Compound

News comes after elevated transaminase levels were seen in some patients taking TAK-475 in clinical trials.

Takeda Discontinues Development Of Cholesterol Compound

News comes after elevated transaminase levels were seen in some patients taking TAK-475 in clinical trials.

Actos Franchise Drives Takeda's Pharmaceutical Sales Growth

Firm continues FDA discussions for new cholesterol candidate Tak-475.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065275

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel